Origin
AI and Data for Cancer Therapeutics
Based based in San Francisco, CA, USA, Origin works in university startup ecosystem, founded in 2019.
Profile
Creating the largest patient-derived cancer single-cell dataset for licensing to pharmaceutical and AI companies. These datasets are unique as they screen the effects of various drugs and genetic medicines under the control of our DNA switches.
Its activity falls under university startup ecosystem; the profile below is assembled from public directory data.
San Francisco, CA, USA is where the company is located.
The company is listed at the Winter 2026 stage of development.
The company reports a headcount in the 4 range.
Public records show total funding of about $12K.
Directory analysis
Origin is a San Francisco‑based startup founded in 2019 that focuses on AI and data for cancer therapeutics. They are building the largest patient‑derived single‑cell cancer dataset, which includes drug and genetic medicine screening under DNA switch control, and plan to license the data to pharmaceutical and AI firms. The company operates with a small team of four employees and has raised $120,000 in funding.
Positioning: Origin operates in the niche intersection of precision oncology data and AI, targeting pharmaceutical and biotech companies that need high‑resolution cellular data for drug discovery. While the dataset promise is compelling, the company remains early stage with limited resources and modest funding.
Note: Origin is a university‑seeded startup in the cancer data space.
Auto-generated directory analysis from public data · updated 8 Oct 2026. Informational only, not investment advice.
| Sector | University startup ecosystem |
|---|---|
| Headquarters | San Francisco, CA, USA |
| Country | United States |
| Founded | 2019 |
| Employees | 4 |
| Stage | Winter 2026 |
| Total funding | $120,000 |
Website: origin.bio
Create a free account